Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment
A 19-year-old girl was diagnosed with type 1 diabetes and showing polydipsia and polyuria. She was double autoantibody-positive and had a diabetes-prone tissue type. She was immediately started on insulin. Fenofibrate treatment (160 mg daily) was initiated seven days after diagnosis. The need for in...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Case Reports in Medicine |
| Online Access: | http://dx.doi.org/10.1155/2020/6865190 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560683383783424 |
|---|---|
| author | Karsten Buschard Laurits J. Holm Ulla Feldt-Rasmussen |
| author_facet | Karsten Buschard Laurits J. Holm Ulla Feldt-Rasmussen |
| author_sort | Karsten Buschard |
| collection | DOAJ |
| description | A 19-year-old girl was diagnosed with type 1 diabetes and showing polydipsia and polyuria. She was double autoantibody-positive and had a diabetes-prone tissue type. She was immediately started on insulin. Fenofibrate treatment (160 mg daily) was initiated seven days after diagnosis. The need for insulin quickly declined, and she took her last dose of insulin 19 days after the first dose of fenofibrate, having regained endogenous control of blood glucose concentrations. She has now been insulin independent for one year and 9 months. Unstimulated C-peptide has increased by 51% (317 to 479 pmol/l), and IA-2 autoantibody level has decreased by 65% (49 to 17 × 103 arbitrary units). Fenofibrate is a widely used drug for reducing triglyceride and cholesterol levels. Fenofibrate reverses and prevents autoimmune diabetes in nonobese diabetic (NOD) mice by increasing the amount of the sphingolipid sulfatide in islets. Sphingolipid metabolism is otherwise abnormal in the islets at diagnosis of type 1 diabetes. In conclusion, we describe a 19-year-old patient with classical newly diagnosed type 1 diabetes, which following fenofibrate treatment has been without insulin for 21 months. |
| format | Article |
| id | doaj-art-9a1fc3e29a0e402bb3f7707bc4fd0bd4 |
| institution | Kabale University |
| issn | 1687-9627 1687-9635 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Medicine |
| spelling | doaj-art-9a1fc3e29a0e402bb3f7707bc4fd0bd42025-02-03T01:27:04ZengWileyCase Reports in Medicine1687-96271687-96352020-01-01202010.1155/2020/68651906865190Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate TreatmentKarsten Buschard0Laurits J. Holm1Ulla Feldt-Rasmussen2The Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkThe Bartholin Institute, Department of Pathology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkDepartment of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen University Hospital, Copenhagen, DenmarkA 19-year-old girl was diagnosed with type 1 diabetes and showing polydipsia and polyuria. She was double autoantibody-positive and had a diabetes-prone tissue type. She was immediately started on insulin. Fenofibrate treatment (160 mg daily) was initiated seven days after diagnosis. The need for insulin quickly declined, and she took her last dose of insulin 19 days after the first dose of fenofibrate, having regained endogenous control of blood glucose concentrations. She has now been insulin independent for one year and 9 months. Unstimulated C-peptide has increased by 51% (317 to 479 pmol/l), and IA-2 autoantibody level has decreased by 65% (49 to 17 × 103 arbitrary units). Fenofibrate is a widely used drug for reducing triglyceride and cholesterol levels. Fenofibrate reverses and prevents autoimmune diabetes in nonobese diabetic (NOD) mice by increasing the amount of the sphingolipid sulfatide in islets. Sphingolipid metabolism is otherwise abnormal in the islets at diagnosis of type 1 diabetes. In conclusion, we describe a 19-year-old patient with classical newly diagnosed type 1 diabetes, which following fenofibrate treatment has been without insulin for 21 months.http://dx.doi.org/10.1155/2020/6865190 |
| spellingShingle | Karsten Buschard Laurits J. Holm Ulla Feldt-Rasmussen Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment Case Reports in Medicine |
| title | Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment |
| title_full | Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment |
| title_fullStr | Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment |
| title_full_unstemmed | Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment |
| title_short | Insulin Independence in Newly Diagnosed Type 1 Diabetes Patient following Fenofibrate Treatment |
| title_sort | insulin independence in newly diagnosed type 1 diabetes patient following fenofibrate treatment |
| url | http://dx.doi.org/10.1155/2020/6865190 |
| work_keys_str_mv | AT karstenbuschard insulinindependenceinnewlydiagnosedtype1diabetespatientfollowingfenofibratetreatment AT lauritsjholm insulinindependenceinnewlydiagnosedtype1diabetespatientfollowingfenofibratetreatment AT ullafeldtrasmussen insulinindependenceinnewlydiagnosedtype1diabetespatientfollowingfenofibratetreatment |